3-methoxy-N-(3-methoxyphenyl)benzamide | 97492-32-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methoxy-N-(3-methoxyphenyl)benzamide
• 英文别名: 3-methoxy-benzoic acid m-anisidide；3-Methoxy-benzoesaeure-m-anisidid；3-Methoxy-benzoesaeure-<3-methoxy-anilid>；Cambridge id 5332338
• CAS: 97492-32-5
• 化学式: C₁₅H₁₅NO₃
• 分子量: 257.289
• InChiKey: DOXZXUCXDALYPI-UHFFFAOYSA-N

物化性质

• 熔点：
  92.5-93.5 °C
• 沸点：
  336.8±27.0 °C(Predicted)
• 密度：
  1.189±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  bis(3-methoxyphenyl)methanimine 在 [双(三氟乙酰氧基)碘]苯 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 0.08h， 以90%的产率得到3-methoxy-N-(3-methoxyphenyl)benzamide
  参考文献：
  名称：

  N–H酮亚胺的高价碘介导的氧化重排：酰胺的Umpolung方法

  摘要：

  描述了在温和的反应条件下通过高价碘介导的NH酮基亚胺的氧化重排来酰胺化酰胺的方法。该策略以高收率提供了具有优异选择性的目标酰胺。此外，初步的机械研究表明，迁移偏好取决于迁移群体的空间效应和电子效应。

  DOI：

  10.1021/acs.joc.7b01468

文献信息

• Supported-Pd catalyzed tandem approach for N-arylbenzamides synthesis
  作者：Sheetal、Ajay Kumar Sharma、Shaifali、Dhananjay Bhattacherjee、Navneet Sharma、Kousik Giri、Pralay Das

  DOI：10.1016/j.mcat.2021.111948

  日期：2021.11

  Aryl iodides as dual arylating agent for C-terminal from oxalic acid [(CO2H)2] and N-terminal from sodium azide (NaN3) for N-aryl benzamides (Ar-CO-NH-Ar) synthesis is a rare invention which has been attempted successfully under this study. A single step tandem approach for the synthesis of N-aryl benzamides has been developed through bifunctional transformation of aryl iodides with in-situ CO from

  芳基碘作为草酸 [(CO 2 H) 2 ] 的 C 端和叠氮化钠 (NaN 3 ) 的 N端双芳基化剂，用于 N-芳基苯甲酰胺 (Ar-CO-NH-Ar) 合成是一种罕见的在这项研究中已成功尝试的发明。通过使用原位CO 从 (CO 2 H) 2和 NaN 3对芳基碘进行双功能转化，开发了一种用于合成 N-芳基苯甲酰胺的单步串联方法遵循羰基化和叠氮化两种不同的途径。发现聚苯乙烯负载的钯 (Pd@PS) 催化剂非常适合在双层小瓶 (DLV) 系统中在碱、配体和无添加剂条件下进行多米诺反应。此外，使用芳基叠氮化物进一步扩展了相同的方法，用于不对称 N-芳基苯甲酰胺 (Ar-CO-NH-Ar') 合成。此外，还进行了 DFT 研究以支持所提出的机制。
• BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS
  申请人：Galley Guido

  公开号：US20090036420A1

  公开（公告）日：2009-02-05

  The present invention relates to methods of treating CNS disorders with a compound of formula I wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof.

  本发明涉及使用式I中的化合物治疗中枢神经系统疾病的方法，其中X、R1、R2、R3、R4、R5、R6、R7和R8如说明书中所定义，并且包括药学上可接受的酸盐。
• Convenient palladium-catalyzed aminocarbonylation of anilines to N-arylbenzamides
  作者：Xiao-Feng Wu、Johannes Schranck、Helfried Neumann、Matthias Beller

  DOI：10.1016/j.tetlet.2011.04.111

  日期：2011.7

  The first one-pot diazotization/aminocarbonylation reaction of anilines to benzamides has been developed. In the presence of commercially available palladium acetate/P(o-Tolyl)(3) as the catalyst system without base at low temperature (50 degrees C) a variety of amides were synthesized in moderate to good yields. (C) 2011 Elsevier Ltd. All rights reserved.
• Syntheses of 3,3'-Dimethoxybenzophenone. Para Substitution in Acylation of the Organocadmium Reagent from m-Haloanisoles^1,2
  作者：L. H. KLEMM、ROGER MANN、C. D. LIND

  DOI：10.1021/jo01097a007

  日期：1958.3
• [EN] THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZAMIDE POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009016088A1

  公开（公告）日：2009-02-05

  The present invention relates to the use of a compound of formula (I), wherein R or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of CNS disorders selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress- related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.